EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut-directed therapy in Parkinson’s disease

Laura Benvenuti, Clelia Di Salvo, Gabriele Bellini, Luisa Seguella, Francesco Rettura, Giuseppe Esposito, Luca Antonioli, Roberto Ceravolo, Nunzia Bernardini, Carolina Pellegrini, Matteo Fornai

Frontiers in Pharmacology · 21.06.2024 · 15

DOI: 10.3389/fphar.2024.1407925 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.06.2024. Verfasst von Laura Benvenuti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is a common and slow-progressing neurodegenerative disorder characterized by motor and non-motor symptoms, including gastrointestinal (GI) dysfunctions. Over the last years, the microbiota-gut-brain (MGB) axis is emerging as a bacterial-neuro-immune ascending pathway that contributes to the progression of PD. Indeed, PD patients are characterized by changes in gut microbiota composition, alterations of intestinal epithelial barrier (IEB) and enteric neurogenic/inflammatory responses that, besides determining intestinal disturbances, contribute to brain pathology. In this context, despite the causal relationship between gut dysbiosis, impaired MGB axis and PD remains to be elucidated, emerging evidence shows that MGB axis modulation can represent a suitable therapeutical strategy for the treatment of PD. This review provides an overview of the available knowledge about the beneficial effects of gut-directed therapies, including dietary interventions, prebiotics, probiotics, synbiotics and fecal microbiota transplantation (FMT), in both PD patients and animal models. In this context, particular attention has been devoted to the mechanisms by which the modulation of MGB axis could halt or slow down PD pathology and, most importantly, how these approaches can be included in the clinical practice.

Schlagwörter

Stichwörter der Autor:innen

Parkinson’s diseaseenteric inflammationenteric nervous systemfecal microbiota transplantationmicrobiota-gut-brain axisprebioticsprobiotics

Autor:innen und Institutionen

  • Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Department of Physiology and Pharmacology "V.Erspamer", Sapienza University of Rome, Rome, Italy.
  • Unit of Gastroenterology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Unit of Histology and Medical Embryology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Zitieren

APA

Benvenuti, L., Di Salvo, C., Bellini, G., Seguella, L., Rettura, F., Esposito, G., Antonioli, L., Ceravolo, R., Bernardini, N., Pellegrini, C., & Fornai, M. (2024). Gut-directed therapy in Parkinson’s disease. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1407925

Vancouver

Benvenuti L, Di Salvo C, Bellini G, Seguella L, Rettura F, Esposito G, et al. Gut-directed therapy in Parkinson’s disease. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1407925

BibTeX
@article{Benvenuti2024,
  author = {Benvenuti, Laura and Di Salvo, Clelia and Bellini, Gabriele and Seguella, Luisa and Rettura, Francesco and Esposito, Giuseppe and Antonioli, Luca and Ceravolo, Roberto and Bernardini, Nunzia and Pellegrini, Carolina and Fornai, Matteo},
  title = {Gut-directed therapy in Parkinson’s disease},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1407925}
}
Kostenlos starten →